909 related articles for article (PubMed ID: 30786811)
1. The HGF-MET axis coordinates liver cancer metabolism and autophagy for chemotherapeutic resistance.
Huang X; Gan G; Wang X; Xu T; Xie W
Autophagy; 2019 Jul; 15(7):1258-1279. PubMed ID: 30786811
[TBL] [Abstract][Full Text] [Related]
2. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
3. Chinese herbal formula QHF inhibits hepatocellular carcinoma metastasis via HGF/c-Met signaling pathway.
Yuan S; Gong Y; Chen R; Du J; Zhang H; Chen T
Biomed Pharmacother; 2020 Dec; 132():110867. PubMed ID: 33075668
[TBL] [Abstract][Full Text] [Related]
4. The EGFR/ErbB3 Pathway Acts as a Compensatory Survival Mechanism upon c-Met Inhibition in Human c-Met+ Hepatocellular Carcinoma.
Steinway SN; Dang H; You H; Rountree CB; Ding W
PLoS One; 2015; 10(5):e0128159. PubMed ID: 26000702
[TBL] [Abstract][Full Text] [Related]
5. C7 peptide inhibits hepatocellular carcinoma metastasis by targeting the HGF/c-Met signaling pathway.
Zhao M; Wang Y; Liu Y; Zhang W; Liu Y; Yang X; Cao Y; Wang S
Cancer Biol Ther; 2019; 20(12):1430-1442. PubMed ID: 31441380
[TBL] [Abstract][Full Text] [Related]
6. MiR-206 inhibits HGF-induced epithelial-mesenchymal transition and angiogenesis in non-small cell lung cancer via c-Met /PI3k/Akt/mTOR pathway.
Chen QY; Jiao DM; Wu YQ; Chen J; Wang J; Tang XL; Mou H; Hu HZ; Song J; Yan J; Wu LJ; Chen J; Wang Z
Oncotarget; 2016 Apr; 7(14):18247-61. PubMed ID: 26919096
[TBL] [Abstract][Full Text] [Related]
7. miR-1-3p and miR-206 sensitizes HGF-induced gefitinib-resistant human lung cancer cells through inhibition of c-Met signalling and EMT.
Jiao D; Chen J; Li Y; Tang X; Wang J; Xu W; Song J; Li Y; Tao H; Chen Q
J Cell Mol Med; 2018 Jul; 22(7):3526-3536. PubMed ID: 29664235
[TBL] [Abstract][Full Text] [Related]
8. PKC mediates fluctuant ERK-paxillin signaling for hepatocyte growth factor-induced migration of hepatoma cell HepG2.
Hu CT; Cheng CC; Pan SM; Wu JR; Wu WS
Cell Signal; 2013 Jun; 25(6):1457-67. PubMed ID: 23524339
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-101-3p suppresses proliferation and migration in hepatocellular carcinoma by targeting the HGF/c-Met pathway.
Liu Y; Tan J; Ou S; Chen J; Chen L
Invest New Drugs; 2020 Feb; 38(1):60-69. PubMed ID: 30929159
[TBL] [Abstract][Full Text] [Related]
10. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
[TBL] [Abstract][Full Text] [Related]
11. Regulation of MET receptor tyrosine kinase signaling by suppressor of cytokine signaling 1 in hepatocellular carcinoma.
Gui Y; Yeganeh M; Donates YC; Tobelaim WS; Chababi W; Mayhue M; Yoshimura A; Ramanathan S; Saucier C; Ilangumaran S
Oncogene; 2015 Nov; 34(46):5718-28. PubMed ID: 25728680
[TBL] [Abstract][Full Text] [Related]
12. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.
Firtina Karagonlar Z; Koc D; Iscan E; Erdal E; Atabey N
Cancer Sci; 2016 Apr; 107(4):407-16. PubMed ID: 26790028
[TBL] [Abstract][Full Text] [Related]
13. Resveratrol suppresses human hepatocellular carcinoma via targeting HGF-c-Met signaling pathway.
Gao F; Deng G; Liu W; Zhou K; Li M
Oncol Rep; 2017 Feb; 37(2):1203-1211. PubMed ID: 28075467
[TBL] [Abstract][Full Text] [Related]
14. Extracellular signal-regulated kinase and Akt activation play a critical role in the process of hepatocyte growth factor-induced epithelial-mesenchymal transition.
Tanahashi T; Osada S; Yamada A; Kato J; Yawata K; Mori R; Imai H; Sasaki Y; Saito S; Tanaka Y; Nonaka K; Yoshida K
Int J Oncol; 2013 Feb; 42(2):556-64. PubMed ID: 23229794
[TBL] [Abstract][Full Text] [Related]
15. ψ-Bufarenogin, a novel anti-tumor compound, suppresses liver cancer growth by inhibiting receptor tyrosine kinase-mediated signaling.
Ding J; Wen W; Xiang D; Yin P; Liu Y; Liu C; He G; Cheng Z; Yin J; Sheng C; Zhang W; Nan F; Ye W; Zhang X; Wang H
Oncotarget; 2015 May; 6(13):11627-39. PubMed ID: 25890498
[TBL] [Abstract][Full Text] [Related]
16. miR-198 inhibits migration and invasion of hepatocellular carcinoma cells by targeting the HGF/c-MET pathway.
Tan S; Li R; Ding K; Lobie PE; Zhu T
FEBS Lett; 2011 Jul; 585(14):2229-34. PubMed ID: 21658389
[TBL] [Abstract][Full Text] [Related]
17. LINC00240 sponges miR-4465 to promote proliferation, migration, and invasion of hepatocellular carcinoma cells via HGF/c-MET signaling pathway.
Bu WJ; Fang Z; Li WL; Wang X; Dong MJ; Tao QY; Zhang L; Xu YQ
Eur Rev Med Pharmacol Sci; 2020 Oct; 24(20):10452-10461. PubMed ID: 33155201
[TBL] [Abstract][Full Text] [Related]
18. Met as a therapeutic target in HCC: facts and hopes.
Giordano S; Columbano A
J Hepatol; 2014 Feb; 60(2):442-52. PubMed ID: 24045150
[TBL] [Abstract][Full Text] [Related]
19. Preparation of a Novel One-Armed Anti-c-Met Antibody with Antitumor Activity Against Hepatocellular Carcinoma.
Yin Y; Guo J; Teng F; Yu L; Jiang Y; Xie K; Jiang M; Fang J
Drug Des Devel Ther; 2019; 13():4173-4184. PubMed ID: 31849449
[TBL] [Abstract][Full Text] [Related]
20. Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications.
García-Vilas JA; Medina MÁ
World J Gastroenterol; 2018 Sep; 24(33):3695-3708. PubMed ID: 30197476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]